A lymphoplasmacytic infiltrate is a collection of immune cells, specifically lymphocytes and plasma cells, found clustered together in a tissue sample. Seeing this phrase on a pathology report does not, by itself, tell you whether something is benign or serious. It describes what the pathologist saw under the microscope, not a diagnosis. The term appears across a wide range of conditions, from autoimmune inflammation and chronic infections to rare blood cancers, and your doctor uses additional context to figure out which category your case falls into.
What the Pathologist Is Describing
When a biopsy is taken from any organ or tissue and examined under a microscope, pathologists describe the types of cells they see and how those cells are arranged. Lymphocytes are small white blood cells that play a central role in immune responses. Plasma cells are a specialized form of lymphocyte whose job is to pump out antibodies. When both cell types show up together in a tissue where they wouldn’t normally be expected in large numbers, pathologists call that a “lymphoplasmacytic infiltrate.”
The word “infiltrate” simply means these cells have moved into the tissue. It carries no inherent implication about whether the process is harmless or dangerous. The pathologist’s job is to describe what the cells look like, how densely packed they are, whether they show signs of abnormal growth, and how they’re distributed in the tissue. Distinguishing a reactive (benign) infiltrate from one driven by a malignancy often requires additional testing beyond the initial look under the microscope.
Benign Causes Are Common
Most lymphoplasmacytic infiltrates turn out to be the immune system doing its job. Chronic infections, autoimmune conditions, and even persistent irritation can trigger the body to send waves of lymphocytes and plasma cells into the affected tissue. In the stomach lining, for instance, a Helicobacter pylori infection is one of the most frequent reasons a pathologist sees excess lymphocytes. Before diagnosing anything more exotic, it’s important to rule out H. pylori and conditions like celiac disease, which can produce similar-looking changes in the gut lining.1Advances in Anatomic Pathology. Lymphocytic Disorders of the Gastrointestinal Tract: A Review for the Practicing Pathologist
Autoimmune thyroid disease, particularly Hashimoto’s thyroiditis, is another classic example. The thyroid gland fills with lymphocytes and plasma cells as the immune system mistakenly attacks thyroid tissue. Researchers have noted that this type of infiltrate can occasionally harbor a monoclonal lymphoid population, a finding more commonly associated with lymphoma, which is why careful evaluation matters even when the underlying condition is autoimmune.2Indian Journal of Pathology and Microbiology. Histopathologic and immunohistochemical features of Hashimoto thyroiditis
Chronic infectious aortitis, an infection of the aorta wall, can also produce dense plasma cell infiltrates that mimic more concerning conditions. In some cases, these infiltrates are rich in a specific antibody subtype called IgG4, which can make the picture look deceptively similar to IgG4-related disease, a distinct condition discussed below.3Cardiovascular Pathology. Dense IgG4 plasma cell infiltrates associated with chronic infectious aortitis: implications for the diagnosis of IgG4-related disease
IgG4-Related Disease
One of the more important conditions associated with lymphoplasmacytic infiltrates is IgG4-related disease, a chronic inflammatory condition that can affect virtually any organ. It was only recognized as a unified disease in the early 2000s, and many clinicians are still getting up to speed on it. The hallmark under the microscope is a dense lymphoplasmacytic infiltrate rich in plasma cells that produce the IgG4 antibody subclass, accompanied by a distinctive swirling pattern of scar tissue called storiform fibrosis, and sometimes inflammation that destroys veins within the tissue (obliterative phlebitis).4Haematologica. IgG4-related disease: what a hematologist needs to know5PubMed. Consensus statement on the pathology of IgG4-related disease
The number of IgG4-positive plasma cells needed to support the diagnosis depends on which organ is being biopsied. In the meninges (the membranes around the brain), more than 10 per microscope field is considered significant; in skin, the threshold is more than 100. Regardless of the site, a ratio of IgG4-positive to total IgG-positive plasma cells above 40% is expected.4Haematologica. IgG4-related disease: what a hematologist needs to know These cutoffs exist because some IgG4 staining shows up in other conditions too, including infections, so the diagnosis can’t rest on a single feature.
IgG4-related disease most commonly affects the pancreas (where it causes autoimmune pancreatitis), the salivary glands, the tissue around the eyes, and the bile ducts, but it has been documented in the kidneys, lungs, aorta, retroperitoneum, and skin. In pancreatic and other organ tissues, high levels of IgG4 staining were found in about 85% of autoimmune pancreatitis cases compared with less than 1% of control specimens.6Clinical Gastroenterology and Hepatology. The use of immunoglobulin g4 immunostaining in diagnosing pancreatic and extrapancreatic involvement in autoimmune pancreatitis The skin form of IgG4-related disease can sometimes be confused with systemic plasmacytosis, a separate condition seen more often in Japan, which also produces dense plasma cell infiltrates in the skin but with a different antibody profile.7Actas Dermo-Sifiliográficas. Skin Biopsy in the Context of Systemic Disease
People younger than 25 with IgG4-related disease tend to have single-organ involvement, often around the eyes, while those over 50 are more likely to have multiple organs affected along with constitutional symptoms like fatigue. Biopsies in both groups show lymphoplasmacytic infiltrate, but older patients more frequently show eosinophils (another type of immune cell) alongside the infiltrate.8Reumatología Clínica. Comparison of IgG4 related disease in patients aged ≤ 25 years (pediatric, adolescent, and young adult) and those aged ≥ 50 years
Lymphoplasmacytic Lymphoma and Waldenström Macroglobulinemia
On the malignant end of the spectrum, a lymphoplasmacytic infiltrate can represent lymphoplasmacytic lymphoma (LPL), a rare type of non-Hodgkin lymphoma. When LPL produces a specific antibody called IgM monoclonal protein that circulates in the blood, the condition is called Waldenström macroglobulinemia.9PubMed Central. Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management This is an uncommon cancer. The bone marrow fills with small, clonal B cells that show the characteristic mix of lymphocytes and plasma cells, and over 90% of cases carry a specific genetic mutation called MYD88 L265P.10PubMed Central. Waldenström Macroglobulinemia – A State-of-the-Art Review: Part 1
Testing for that MYD88 mutation has become a key diagnostic tool. In one study, it was present in 92% of LPL cases.11PubMed. Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia and description of its mutational profiles by targeted NGS The mutation helps pathologists separate LPL from marginal zone lymphoma, another low-grade lymphoma that can look strikingly similar in the bone marrow. Both can show up with overlapping cell types and staining patterns, making the distinction genuinely difficult without molecular testing.12PubMed Central. Lymphoplasmacytic lymphoma and marginal zone lymphoma involving bone marrow: A diagnostic dilemma
Waldenström macroglobulinemia is typically a slow-growing cancer. Not everyone diagnosed with it needs treatment right away. When treatment is needed, the most common first-line approach combines chemotherapy with the anti-CD20 antibody rituximab, with bendamustine-rituximab being the most frequently prescribed combination. Newer targeted therapies, particularly BTK inhibitors like ibrutinib and zanubrutinib, have become important options and show strong effectiveness.13PubMed. SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia In a large multicenter analysis, chemo-immunotherapy achieved an overall response rate of about 68%, while BTK inhibitors and proteasome inhibitor-based regimens achieved rates in the mid-50s percent range.14Blood. Clinical Outcomes of Lymphoplasmacytic Lymphoma / Waldenstrom Macroglobulinemia (LPL/WM) in the Targeted Therapy Era: A US Multicenter Retrospective Analysis
How Pathologists Sort Out What They’re Seeing
Because a lymphoplasmacytic infiltrate can mean so many different things, pathologists rely on a layered approach. Good-quality tissue sections are the starting point, ideally from tissue that was properly fixed and sliced thin enough to preserve fine details.15Indian Journal of Pathology and Microbiology. Plasmacytic or lymphoplasmacytic infiltrate in lymph nodes: Diagnostic approach and differential considerations From there, the pathologist assesses density, distribution, and the presence of worrisome features.
In breast tissue, for example, researchers found that benign lymphoplasmacytic infiltrates tend to be less dense than those caused by MALT lymphoma, show more scar tissue, and have fewer B cells overall. Benign cases predominantly contained IgG-positive plasma cells, while lymphomas were predominantly IgM-positive, a reversal that helps with classification.16PubMed. Evaluating breast lymphoplasmacytic infiltrates: a multiparameter immunohistochemical study, including assessment of IgG4
In the stomach, features strongly suggestive of lymphoma include prominent lymphoepithelial lesions (where lymphocytes invade and disrupt the glandular lining), moderate cellular atypia, and Dutcher bodies (abnormal accumulations of antibody material inside cell nuclei). A study evaluating gastric biopsies found that one or more of these features appeared in about 72% of gastric lymphomas, while none were seen in benign cases.17PubMed. Lymphoid infiltrates of the stomach. Evaluation of histologic criteria for the diagnosis of low-grade gastric lymphoma on endoscopic biopsy specimens
For skin biopsies, the challenge is similar. No single microscopic feature reliably separates a benign lymphoid infiltrate from an early cutaneous lymphoma. The gold standard remains careful correlation between the clinical picture and the pathology findings, even with modern immunohistochemistry and molecular testing available.18PubMed Central. Approach to Cutaneous Lymphoid Infiltrates: When to Consider Lymphoma?
When It Shows Up in Unexpected Places
Lymphoplasmacytic infiltrates sometimes appear where clinicians aren’t initially looking for them. Kidney biopsies performed to evaluate rising creatinine levels or protein in the urine occasionally reveal a previously undiagnosed lymphoplasmacytic cancer as the underlying cause. In one case series, about 61% of patients with lymphoplasmacytic neoplasms involving the kidney had their lymphoma first diagnosed through the kidney biopsy itself. Over half of these patients also had a separate type of kidney damage occurring alongside the cancer, including immune-complex-driven glomerular injury and amyloid deposits caused by the tumor’s antibody production.19PubMed. Patterns of glomerular injury in kidneys infiltrated by lymphoplasmacytic neoplasms
The eye area is another site where these infiltrates show up in ways patients don’t expect. A 63-year-old man with known Waldenström macroglobulinemia developed painless swelling of both eyelids that turned out to be lymphoplasmacytic lymphoma infiltrating both lacrimal (tear-producing) glands.20PubMed Central. Lymphoplasmacytic lymphoma infiltrating both lacrimal glands in a patient with Waldenström’s macroglobulinemia Painless swelling, drooping lids, and mild redness of the eye surface were the only symptoms. These presentations are a reminder that a lymphoplasmacytic process can announce itself through vague symptoms that don’t immediately suggest a blood disorder.
What It Can Mean for Prognosis
Interestingly, the presence of a lymphoplasmacytic infiltrate is not always bad news, even in the context of cancer. In hepatocellular carcinoma (the most common type of liver cancer), tumors that contained a lymphoplasmacytic infiltrate were associated with significantly longer overall survival and longer recurrence-free survival compared with tumors that lacked one. The infiltrate was an independent predictor of both outcomes even after accounting for other risk factors like vascular invasion and tumor spread within the liver.21PLOS ONE. Histologic Assessment of Intratumoral Lymphoplasmacytic Infiltration Is Useful in Predicting Prognosis of Patients with Hepatocellular Carcinoma
This fits a broader pattern in oncology: the presence of immune cells within a tumor often signals that the body is mounting a response against the cancer. It doesn’t guarantee a better outcome, but across several cancer types, tumors with robust immune infiltrates tend to behave less aggressively than those that have managed to shut the immune system out. So if your pathology report mentions a lymphoplasmacytic infiltrate within a tumor, it may actually be a favorable sign depending on the cancer type.
What to Do When You See It on Your Report
If your pathology report mentions a lymphoplasmacytic infiltrate, the first thing to understand is that this is a description, not a diagnosis. The pathologist is telling your doctor what cell types are present and how the tissue looks. The diagnosis comes from combining that description with your symptoms, blood work, imaging, and sometimes additional staining or molecular tests on the same tissue.
In many cases, the finding reflects a straightforward immune response to infection or autoimmune activity, and the treatment targets that underlying cause. If an H. pylori infection is driving gastric inflammation, treating the infection resolves the infiltrate. If Hashimoto’s thyroiditis is responsible, thyroid hormone replacement addresses the clinical problem regardless of the ongoing infiltrate.
For IgG4-related disease, corticosteroids are usually the first-line treatment and are often highly effective at reducing organ swelling and suppressing the inflammatory infiltrate. Steroid-sparing agents and rituximab are used for relapsing or steroid-resistant cases. The condition tends to respond well to treatment, though relapses are common and long-term follow-up matters.
For lymphoplasmacytic lymphoma and Waldenström macroglobulinemia, as described above, the approach depends on whether symptoms are present. Many patients are monitored without treatment for months or even years (“watch and wait”) until symptoms develop or blood counts change enough to warrant intervention.
Skin Lesions and the Benign Lymphoplasmacytic Plaque
A specific skin condition called benign lymphoplasmacytic plaque deserves a brief mention because it can cause unnecessary worry. It shows up as a solitary, slowly growing plaque on the skin, and under the microscope it shows a dense lymphoplasmacytic infiltrate that can look alarming. Multiple histological patterns have been described, ranging from a superficial band-like pattern to deeper dermal involvement, with plasma cells making up anywhere from 5% to 40% of the infiltrate. Granulomas and giant cells appear in only about 30% of cases.22Journal of the European Academy of Dermatology and Venereology. Diagnostic approach in lymphoplasmacytic plaque This condition is benign and can be treated with surgical removal, though the main challenge is making sure it truly is benign and not an early cutaneous lymphoma masquerading as one.
Why the Same Term Can Mean Very Different Things
The reason “lymphoplasmacytic infiltrate” appears in so many unrelated conditions is that lymphocytes and plasma cells are the immune system’s general-purpose responders to chronic stimulation. Whether the trigger is a persistent infection, an autoimmune attack, or a slow-growing lymphoma, the body uses the same cell types to respond. The infiltrate is the immune system’s accent, not its sentence. What the sentence actually says depends on the pattern, the density, the molecular markers, and the clinical story around it.
If you’re reading your own pathology report and see this term, resist the urge to jump to the worst-case scenario. Ask your doctor what additional tests have been ordered, whether the infiltrate appears reactive or raises concern for something more serious, and what the next step looks like in your specific situation. In most cases, the answer will involve either treating a known underlying condition or getting one more round of testing to pin down exactly what is going on.